Colorectal cancer: Impact of primary tumor location on genetic alterations.

Authors

Mohamed Salem

Mohamed E. Salem

Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

Mohamed E. Salem , Heinz-Josef Lenz , Joanne Xiu , Jimmy J. Hwang , Philip Agop Philip , Anthony Frank Shields , John Marshall

Organizations

Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, Caris Life Sciences, Phoenix, AZ, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, Karmanos Cancer Institute, Detroit, MI, Wayne State University, Karmanos Cancer Institute, Detroit, MI, Georgetown University Medical Center, Washington, DC

Research Funding

Other

Background: Recent data show that patients with left sided colon tumors (LT) have better survival and respond differently to biologics compared to patients with right-sided tumors (RT), likely due to molecular differences. We sought to examine these differences. Methods: Primary colorectal tumors (n = 1730) with origins clearly defined as RT (cecum to hepatic flexure; n = 273), LT (splenic flexure to sigmoid colon; n = 585), or rectal (RC; n = 872) were examined by NextGen sequencing, protein expression and gene amplification. Tumor mutational load (TML) was calculated in 1001 of these tumors using only somatic nonsynonymous missense mutations. Chi-square was used for comparison. Results: When compared to LT, RT carried a significantly higher rate of BRAF (25% vs 7%; p < 0.0001), PTEN (5.4% vs 1.3%; p = 0.008), and ATM (4% vs 1%; p = 0.04) mutations. RT were likely to have more MSI-high tumors (22% vs 5%; p < 0.0001) and PD-1 overexpression (58% vs 44%; p = 0.01). There were no differences in the rate of KRAS (50% vs 42%; p = 0.07) or NRAS mutations (2.2% vs 3.4%; p = 0.4). When compared to RC, RT had a higher rate of BRAF (25% vs 3%; p = 7E-07), PIK3CA (22% vs 11%; p = 0.001), CTNNB1 (3% vs 0.3%; p = 0.02); ATM (3% vs 1%; p = 0.04), PTEN (5% vs 1%; p = 0.004), and BRCA1 mutations (4% vs 0%; p = 0.02), and a lower rate of TP53 (56% vs 71%; p = 0.001) and APC (53% vs 66%; p = 0.003) mutations. When compared to RC, LT showed higher rates of BRAF (6.7% vs 3.2%; p = 0.04) and CTNNB1 (2.1% vs 0.3%; p = 0.04) mutations, and a higher rate of MSI-high tumors (4.6% vs 0.7%; p = 0.04), whereas RC had a higher rate of KRAS mutation (50% vs 42%; p = 0.04). There were no differences between RT, LT, and RC for the frequency of PD-L1 (2%, 2%, and 1%) or Her-2 (1%, 2%, and 3%) overexpression, although Her-2 amplification was significantly different (1%, 3%, and 5%, RT vs RC; p = 0.03). Mean TML was 12, 11, and 8 mutations/megabase for RT, LT, and RC, respectively (RT vs RC; p = 0.01). There was a correlation between TML and PD-L1 (p = 0.04) and PD-1 (p = 0.01). Conclusions: Tumors arising in the right colon carry genetic alterations that are different from LT as well as RC. However, it appears that CRCs carry a continuum of molecular alterations from the right to the left side, rather than displaying sharp, clear-cut differences.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3578)

DOI

10.1200/JCO.2017.35.15_suppl.3578

Abstract #

3578

Poster Bd #

201

Abstract Disclosures

Similar Abstracts

First Author: Maher Albitar

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Mutation status of full RAS and BRAF in 169 Moroccan patients with colorectal cancer.

First Author: Sara El Zaitouni

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using 18F-BMS-986229 PET.

First Author: Samuel Louis Cytryn

Abstract

2023 ASCO Gastrointestinal Cancers Symposium

Beyond CPS for PD-L1 scoring: Genetic alterations that impact efficacy of immunotherapy in hepatocellular carcinoma (HCC).

First Author: Emil Lou